Latest news

• Roche sets disruptive price for new MS drug Ocrevus in US

  remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).

• NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

  NICE backtracks on Biogen's multiple sclerosis drug Zinbryta. Recommends the treatment after new cost effectiveness and a discount provided. ... Zinbryta is also being considered for use by the NHS in Scotland, and the Scottish Medicines Consortium (SMC)

• Biogen elevates Vounatsos to top seat

  recently-approved Zinbryta (daclizumab) and bringing forward phase III Alzheimer's disease candidate aducanumab.

• Biogen's CEO Scangos to step down

  Vounatsos highlighted the prospects for just-approved Zinbryta (daclizumab), a once-monthly MS therapy which is due for launch in the US and Germany next month, as well as the

• Roche's MS drug Ocrevus awarded priority review by FDA

  If approved Ocrevus will compete for MS market share with Biogen's recently-approved Zinbryta, while Novartis has an anti-B cell candidate in its pipeline, which the company claims has